Literature DB >> 28145032

National treatment programme of hepatitis C in Egypt: Hepatitis C virus model of care.

W El-Akel1, M H El-Sayed2, M El Kassas3, M El-Serafy1, M Khairy1, K Elsaeed4, K Kabil5, M Hassany6, A Shawky4, A Yosry1, M K Shaker7, Y ElShazly4, I Waked8, G Esmat1, W Doss1.   

Abstract

Hepatitis C virus (HCV) infection is a major health problem in Egypt as the nation bears the highest prevalence rate worldwide. This necessitated establishing a novel model of care (MOC) to contain the epidemic, deliver patient care and ensure global treatment access. In this review, we describe the process of development of the Egyptian model and future strategies for sustainability. Although the magnitude of the HCV problem was known for many years, the HCV MOC only came into being in 2006 with the establishment of the National Committee for Control of Viral Hepatitis (NCCVH) to set up and implement a national control strategy for the disease and other causes of viral hepatitis. The strategy outlines best practices for patient care delivery by applying a set of service principles through identified clinical streams and patient flow continuums. The Egyptian national viral hepatitis treatment programme is considered one of the most successful and effective public health programmes. To date, more than one million patients were evaluated and more than 850 000 received treatment under the umbrella of the programme since 2006. The NCCVH has been successful in establishing a strong infrastructure for controlling viral hepatitis in Egypt. It established a nationwide network of digitally connected viral hepatitis-specialized treatment centres covering the country map to enhance treatment access. Practice guidelines suiting local circumstances were issued and regularly updated and are applied in all affiliated centres. This review illustrates the model and the successful Egyptian experience. It sets an exemplar for states, organizations and policy-makers setting up programmes for care and management of people with hepatitis C.
© 2017 John Wiley & Sons Ltd.

Entities:  

Keywords:  Egypt; National Committee for Control of Viral Hepatitis; chronic HCV; model of care

Mesh:

Substances:

Year:  2017        PMID: 28145032     DOI: 10.1111/jvh.12668

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  33 in total

1.  Interleukin 28A.rs12980602 and interleukin 28B.rs8103142 genotypes could be protective against HCV infection among Egyptians.

Authors:  Zainab A Zakaria; Susanne Knapp; Mohamed Hashem; Hassan Zaghla; Mark Thursz; Imam Waked; Sayed Abdelwahab
Journal:  Immunol Res       Date:  2019-02       Impact factor: 2.829

2.  Hepatitis C care continuum and associated barriers among people who inject drugs in Chennai, India.

Authors:  Eshan U Patel; Sunil S Solomon; Allison M Mcfall; Aylur K Srikrishnan; Amrose Pradeep; Paneerselvam Nandagopal; Oliver Laeyendecker; Aaron A R Tobian; David L Thomas; Mark S Sulkowski; M Suresh Kumar; Shruti H Mehta
Journal:  Int J Drug Policy       Date:  2018-04-19

3.  A significant upsurge of body mass index in patients with chronic hepatitis C successfully treated with direct-acting antiviral regimens.

Authors:  Mohamed El Kassas; Mohamed Alboraie; Mervat Naguib; Heba Omar; Adel El Tahan; Inas Moaz; Mohamed Abdellah; Sameera Ezzat; Mohamed-Naguib Wifi; Ahmed F Sherief; Mohamed Eltabbakh; Lobna Abdelsalam; Amal H Eissa; Dalia Omran
Journal:  Turk J Gastroenterol       Date:  2019-08       Impact factor: 1.852

4.  6th Canadian Symposium on Hepatitis C Virus: Delivering a cure for hepatitis C infection-What are the remaining gaps?

Authors:  Sarwat Khan; Annie Bernier; Dustin Dapp; Emmanuel Fortier; Mel Krajden; Alexandra King; Jason Grebely; Selena M Sagan; Curtis L Cooper; Angela M Crawley
Journal:  Can Liver J       Date:  2018-07-17

5.  Schistosoma mansoni infection and the occurrence, characteristics, and survival of patients with hepatocellular carcinoma: an observational study over a decade.

Authors:  Hend Ibrahim Shousha; Ashraf Omar Abdelaziz; Mohamed Mahmoud Nabeel; Dalia Abdelhamid Omran; Ahmed Hosni Abdelmaksoud; Tamer Mahmoud Elbaz; Ayman Salah; Shady Tarek ElGhazaly Harb; Karim Adel Hosny; Ayman Osman; Mira Atef; Abdelazez Gaber; Naglaa Ali Zayed; Ayman Abdelhady Yosry; Rania Leithy
Journal:  Pathog Glob Health       Date:  2021-09-08       Impact factor: 3.735

6.  Discovery and Development of Antiviral Therapies for Chronic Hepatitis C Virus Infection.

Authors:  Miguel Angel Martinez; Sandra Franco
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

7.  Early fibrosis regression by shear wave elastography after successful direct-acting anti-HCV therapy.

Authors:  Mohamed Ahmed Samy Kohla; Ahmed El Fayoumi; Mohamed Akl; Mervat Abdelkareem; Mahmoud Elsakhawy; Sally Waheed; Mai Abozeid
Journal:  Clin Exp Med       Date:  2019-12-02       Impact factor: 3.984

Review 8.  Hepatitis C Virus Epidemiology and the Impact of Interferon-Free Hepatitis C Virus Therapy.

Authors:  Jeffrey V Lazarus; Elena Roel; Ahmed M Elsharkawy
Journal:  Cold Spring Harb Perspect Med       Date:  2020-03-02       Impact factor: 6.915

9.  Detection of hepatitis C virus (HCV) RNA in the peripheral blood mononuclear cells of HCV-infected patients following sustained virologic response.

Authors:  Mahmoud A Khattab; Yehia Zakaria; Eslam Sadek; Aliaa S Abd El Fatah; Magdy Fouad; Muhammed Khattab; Hend M Moness; Nashwa Mohamed Adel; Elham Ahmed
Journal:  Clin Exp Med       Date:  2022-01-23       Impact factor: 3.984

10.  Generic sofosbuvir/ledipasvir for the treatment of genotype 4 chronic hepatitis C in Egyptian children (9-12 years) and adolescents.

Authors:  Hanaa A El-Araby; Behairy E Behairy; Mohamed A El-Guindi; Nermin M Adawy; Alif A Allam; Ahmad M Sira; Mohamed A Khedr; Ibrahim A Elhenawy; Gihan A Sobhy; Hosam El Din M Basiouny; Menan E Salem; Samira A Abdel-Aziz; Ola A Fouad; Bassam A Ayoub
Journal:  Hepatol Int       Date:  2019-09-12       Impact factor: 9.029

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.